Steven Quay

The American Society for Investigative Pathology operates as a biotechnology company.

The Association for Molecular Pathology develops molecular diagnostics. The American company was founded by Jeffrey Cossman.

Association for Pathology Informatics, Inc. promotes the field of pathology informatics as an academic and a clinical subspecialty of pathology. It engages in collecting, examining, reporting, and storing sets of data derived from tests performed in clinical laboratories, anatomic pathology laboratories, or research laboratories in order to improve patient care and enhance understanding of disease-related processes. The company was founded in 2000 and is headquartered in Pittsburgh, PA.

The Society for Laboratory Automation & Screening (SLAS) sets standards for microplate development through its Microplate Standards Advisory Committee. The non-profit company is based in St. Charles, IL. SLAS offers various platforms for education, scientific publishing, collaboration, networking, and career advancement for its international community. The company has developed a new micro-credentials program exclusively for the life sciences industry. SLAS's mission is to connect laboratory technology providers with laboratory technology users.

VitalMedix, Inc., is a Minneapolis-based, development-stage company that has developed a proprietary, rapidly deployable formulation called Tamiasyn that will potentially allow the human body to endure severe blood loss for an extended period of time and also inhibit human organ damage during the resuscitation process. VitalMedix intends to market Tamiasyn in combination with a hemorrhagic shock treatment system named O2Rescue. It is hoped that this system will offer first responders, trauma center surgeons and military medics a simple, safe and reliable product for preventing serious organ damage and death among victims of severe blood loss. It is believed that Tamiasyn might also have potential applications during invasive surgery and organ preservation, and in cases of stroke. Since 2005, the research conducted by VitalMedix has been funded by the Defense Advanced Research Projects Agency (DARPA). Much of this research has been conducted at the University of Minnesota, which is a shareholder in VitalMedix, Inc. The company now holds an exclusive, global license from the University of Minnesota for Tamiasyn. In order for human trials to begin, the Company will need to have an approved Investigational New Drug [IND] application on file with FDA. The IND provides a compilation of all R&D conducted to date including formulation development, animal pharmacology and toxicology, and supportive literature. The IND must also include a plan for intended additional animal studies and clinical trials. Typically, the time to market for a viable drug candidate is 8-10 years. However, manufacturers can request 'fast track' designation for their product and indication for use if the product offers potential as a life-saving technology superior to current therapies. If designated, FDA will work closely with the manufacturer and provide expedited review and approval times if appropriate. VitalMedix, Inc. intends to request fast track status for Tamiasyn in hemorrhagic shock.

MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY.

Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA.

National Reference Laboratory For Breast Health, Inc. provides testing facilities. The firm’s services are designed to provide critical information that empowers women and their healthcare providers to take charge of and protect their breast health. The company is headquartered in Seattle, WA.